THE CLINICAL VALUE OF COMBINED FDG PET/CT IMAGING IN RESPONSE EVALUATION AFTER RADIOCHEMOTHERAPY IN PATIENTS WITH POTENTIALLY OPERABLE LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA

THE CLINICAL VALUE OF COMBINED FDG PET/CT IMAGING IN RESPONSE EVALUATION AFTER RADIOCHEMOTHERAPY IN PATIENTS WITH POTENTIALLY OPERABLE LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA - ECLYPS-study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36288

Enrollment

Registered

2011-02-14

Start date

2011-04-29

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head and neck cancer head and neck squamous cell carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: operable N2/N3 squamous cell carcinoma of head and neck planned treatment of chemoradiation (with curative intent)

Exclusion criteria

Exclusion criteria: Age

Design outcomes

Primary

Measure	Time frame
The negative predictive value (NPV) of FDG PET/CT for detecting residual nodal involvement	—

Secondary

Measure	Time frame
1. The sensitivity and specificity of high-resolution FDG PET/CT 2. The sensitivity and specificity of dual time point FDG PET/CT 3. The number of additional distant metastases found on PET and the % change in patient management 4. DFS and OS, correlation with baseline SUV, early PET response and with HPV status	—

Countries

Netherlands

Outcome results